Transmission characteristics of variably protease-sensitive prionopathy.
The phenotype of human prion diseases is highly heterogeneous. This characteristic is largely due to the variable genotype at codon 129, the site of a methionine/ valine (MV) polymorphism in the human PrP gene, and the molecular characteristics of the associated Pr[P.sup.Sc] (5). A further major distinction that has been applied to human prion diseases for years is based on the experimental transmissibility of these diseases to hosts thought to be permissive for exogenous human Pr[P.sup.Sc] (6). Based on this principle, the sporadic form of Creutzfeldt-Jakob disease (sCJD) belongs to the transmissible disease group, whereas most of the Gerstmann-Straussler-Scheinker diseases (GSS), a group comprising exclusively inherited forms, were considered difficult to transmit or not transmissible (7-10). However, an increasing number of findings have challenged this distinction. Replication of infectious Pr[P.sup.Sc] occurs in the absence of clinical signs in the host, or even in the absence of detectable disease, by histologic and Western blot (WB) examinations. Yet, infectivity can be demonstrated in subsequent passages to more susceptible hosts (9,11,12). Finally, disease transmissibility has recently been demonstrated for a subtype of GSS previously thought to be nontransmissible (8,10,13).
In 2008 and 2010, we introduced a novel human prion disease, presumably sporadic, that we named variably protease-sensitive prionopathy (VPSPr) (14-16). VPSPr differs from sCJD in several aspects. The clinical presentation and the frequent slow progression evoke the features of atypical dementias, such as frontotemporal dementia, diffuse Lewy body disease, or normal pressure hydrocephalus (17). The flocculent PrP immunostaining pattern, which includes the frequent presence of PrP peculiar amyloid plaques, differs from those of other sporadic prion diseases. However, the most distinctive VPSPr feature rests on the characteristics of the associated Pr[P.sup.Sc], especially the electrophoretic profile and resistance to the commonly used protease, such as proteinase K (PK) (14,15,17). VPSPr-associated, PK-resistant Pr[P.sup.Sc] (resPr[P.sup.Sc]) forms a distinctive 5-band electrophoretic profile, comprising various fragments truncated at the N terminal and at least 1 fragment truncated at both N and C terminals, which consequently lacks the GPI (glycosylphosphatidylinositol) anchor (14). Furthermore, the N-truncated fragments do not include the diglycosylated Pr[P.sup.Sc] iso-forms but only 1 of 2 monoglycosylated and the unglycosylated isoforms (18), and upon cleavage of the glycans, these fragments form 3 PK-resistant WB bands in VPSPr preparations. In contrast, the electrophoretic profile of sCJD resPr[P.sup.Sc] is characterized by 3 bands, including diglycosylated, 2 monoglycosylated, and unglycosylated isoform, all of which harbor the GPI anchor and form only 1 band after glycan removal (19). However, VPSPr also occasionally displays small amounts of typical 3 electro-phoretic band-forming resPr[P.sup.Sc] on WB of basal ganglia and other deep cerebral structures (14). On the whole, the VPSPr 5-band ladder profile is more akin to the electro-phoretic profile of Pr[P.sup.Sc] in most GSS subtypes, although contrary to GSS, no mutation in the PrP gene open reading frame has been observed in VPSPr (14-16). Given this similarity, Zou et al. hypothesized that VPSPr is the sporadic form of GSS (15). Like sCJD, VPSPr affects persons harboring each of 3 Pr[P.sup.C] 129 genotypes: methionine and valine homozygosity (MM, VV) and MV heterozygosity. The 3 genotypic subtypes of VPSPr differ slightly in clinical presentation, duration, histopathologic features, and PK resistance of the Pr[P.sup.Sc] (15).
The similarity in the Pr[P.sup.Sc] electrophoretic profiles with GSS, which was regarded as not transmissible, called into question the transmissibility of VPSPr and prompted use of the term prionopathy rather than prion disease. The present study addresses this issue. Transgenic (Tg) mice expressing various levels of human Pr[P.sup.C] harboring methionine (M) or valine (V) at position 129 underwent intracranial inoculation with brain homogenates (BH) from several human case-patients with VPSPr associated with each of the three 129 genotypes (15). Surprisingly, VPSPr was transmitted as an asymptomatic disease characterized by focal accumulation of VPSPr-like Pr[P.sup.Sc] in the first passage, but no prion disease could be demonstrated in the second passage.
Materials and Methods
VPSPr Case-Patients and Controls
We conducted this study during 2007-2013. Twelve case-patients with VPSPr (6 with VPSPr-129VV, 4 with VPSPr-129MV, and 2 with VPSPr-129MM) provided the inocula used in the first passage. The second passage inocula were obtained from Tg mice challenged at first passage with BH from frontal cortex and putamen of 1 case patient with VPSPr-129VV and 1 with VPSPr-129MM. Two sets of experiments were conducted to generate negative controls by using Tg mice from the same lines: 1) age-matched Tg mice that were not inoculated and 2) age-matched Tg mice challenged with noninfectious BH from mice of the same genetic background. Positive controls were obtained from the same 129M and 129V Tg mice lines inoculated with BH from 5 subtypes of sCJD, sCJDMM1, sCJDMM2, sCJDVV1, sCJDVV2, and sCJDMV2, maintaining the host/donor homology of codon 129. Finally, six 129V Tg mice were euthanized 35 days postinoculation (dpi) with VPSPr-129VV, and the presence of the inoculum was searched by immunohistochemistry and immunoblotting.
Four mouse lines with different Pr[P.sup.C] expression levels were used. The first line was a Tg362 mouse line expressing human Pr[P.sup.C]-129V on a mouse Pr[P.sup.C] null background at [approximately equal to] 8-fold normal human brain levels, hereafter identified as Tg(HuPrP129V) x 8. This line was generated following previously described methods (20). For the next 2 lines,Tg40 and Tg21 were generated by replacing the mouse PrP open reading frame in the murine halfgenomic PrP clone in plasmid pHGPRP (21) with that of human PrP-129M or human PrP-129V as reported (22). The generated Tg mice harbored a wild-type FVB background and bred with FVB/PrP null mice (23) to obtain Tg mice in mouse PrP null FVB background. For the fourth line, the generated Tg40 mouse line expressing human Pr[P.sup.C]-129M at [approximately equal to] 1-fold normal mouse brain level, identified as Tg(HuPrP129M)*1, was then self-bred to obtain the Tg40h mouse line. The generated Tg40h expressing human Pr[P.sup.C]-129M at ~2-fold normal mouse brain levels, was identified as Tg(HuPrP129M) x 2. The Tg21 mouse line expressing human Pr[P.sup.C]-129V at [approximately equal to] 3-fold normal mouse brain levels was identified as Tg(HuPrP129V) x 3.
Ten percent or 1% BH in 5% glucose or phosphate buffered saline were generated from the frontal cortex, occipital cortex, or putamen. It was inoculated intracerebrally according to procedures previously described (20,22).
We conducted animal experiments in strict accordance with the recommendations in the guidelines of the Code for Methods and Welfare Considerations in Behavioral Research with Animals (directive 86/609EC). All efforts were made to minimize suffering. Experiments were approved by the Committee on the Ethics of Animal Experiments of the Spanish National Instutute for the Agricultural and Food Research and Technology; permit no. CEEA 2011/046.
Histology and Immunohistochemistry
Standard histologic and immunohistochemical examinations were conducted at 4 brain levels. These were basal ganglia (bregma + [approximately equal to] 0.14 mm), thalamus (bregma - [approximately equal to] 1.46 mm), posterior hippocampus (bregma - [approximately equal to] 2.92 mm), and anterior cerebellum (bregma - [approximately equal to] 6.00 mm), on paraffin sections stained with hematoxylin and eosin or probed with the 3F4 antibody to the prion protein (PrP) (1:1,000-1,400) (24).
Conventional immunoblotting was conducted on frozen brain tissues homogenized in glucose solution to make 10% BH. To detect PK-resistant Pr[P.sup.Sc], we mixed the 10% BH with an equal volume of 2x lysis buffer. BH was treated with different amounts of PK (Sigma Chemical Co., St. Louis, MO, USA) ranging from 0 [micro]g/mL to 50 [micro]g/mL. The samples untreated or treated with PK, equivalent to 0.5-2 mg of wet tissues, were loaded onto 15% Tris-HCl Criterion precast gels (Bio-Rad Laboratories, Hercules, CA, USA) for SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and immunoblotted with the widely used PrP antibody 3F4 against human PrP106-112 (15) or 1E4 against human PrP97-105 (25) (Cell Sciences, Inc., Canton, MA, USA). When required, PrP was deglycosylated with PNGase F (New England Biolabs, Beverly, MA, USA) before immunoblotting following the manufacturer's instructions.
Histologic and Immunohistochemical Analyses
We found that 54% of the Tg mice belonging to 3 lines expressing 129V or 129M human PrP showed histologic abnormalities after inoculation of BH from 6 persons with symptomatic VPSPr (inoculum from 1 presymptomatic but histopathologically and immunochemically confirmed person with VPSPr did not transmit) (Table 1). All 30 positive Tg mice were asymptomatic until they were culled, after incubation periods of up to 800 days. Although the low number of mice inoculated with VPSPr-129MM made the comparison difficult, no major differences in the rate of transmission were detected between Tg(HuPrP129V) mice challenged with VPSPr-129VV and Tg(HuPrP129M) mice challenged with VPSPr-129MM. Similarly, we detected no significant difference in plaque prevalence between Tg mice expressing Pr[P.sup.C] at levels x8 and x3 normal (Table 1). Affected Tg mice were observed only when the 129 genotype of the VPSPr inoculum matched that of the host (Table 2); that is, neither positive Tg(HuPrP129M) nor Tg(HuPrP129V) mice were observed after inoculation with VPSPr-129MV and VPSPr-129VV or VPSPr-129MV BH, respectively. However, VPSPr-129MM transmission to Tg(HuPrP129V) was not tested, and Tg(HuPrP129M)x1, but not Tg(HuPrP129M)x2, was used for transmission of VPSPr-129VV.
The histologic lesions included 2 types. The most common lesion consisted of individual or aggregates of prion plaques often in a row preferentially located immediately below the corpus callosum at the border with the alveus of the hippocampus, which might represent the subependymal region of the lateral ventricles. We occasionally saw individual plaques in other periventricular regions but rarely in the parenchyma (Figures 1, 2). The lesion of the second type consisted of focal spongiform degeneration involving the layer lacunosum moleculare of the hippocampus (Figure 1). This lesion was seen almost exclusively in Tg(HuPrP129V)x8 and predominantly after inoculation of VPSPr BH from the basal ganglia. PrP immunostaining intensely enhanced the plaques and demonstrated PrP granular deposits in the focal areas of spongiform degeneration. Although plaques appeared very compact in Tg(HuPrP129V) mice inoculated with VPSPr-129VV, plaques in Tg(HuPrP129M) mice after VPSPr-129MM inoculation were less well formed and were often replaced by loose aggregates of irregular granules (Figure 1). The topographic distribution of the plaque deposits and focal spongiform change are shown in Figure 2.
Neither prion-related lesions nor Pr[P.sup.Sc] were observed in 23 age-matched Tg(HuPrP129)Vx8 mice that had not been inoculated or had undergone inoculations with noninfectious BH (Table 3). As expected, the 3 Tg(HuPrP) mouse lines used for VPSPr transmission easily transmitted sCJD subtypes that were 129 genotypically compatible with the host PrP, indicating that the Tg mice used for VPSPr transmission are competent to propagate classical human prion diseases (Table 3). No PrP immunostaining was detected in the 6 Tg(HuPrP129V)x8 35 dpi with VPSPr-129VV BH.
Thirteen (34%) of the 38 VPSPr-inoculated Tg (HuPrP129V)x8 mice examined showed a definitively positive WB, despite the mouse BH treatment with a wide range of PK to maximize the recovery of Pr[P.sup.Sc], including Pr[P.sup.Sc] species with low resistance to PK. The 34% prevalence of positive cases harboring detectable Pr[P.sup.Sc] was nearly half that of Pr[P.sup.Sc]-positive Tg mice detected at histopathologic examination (Table 1). Tg mouse resPr[P.sup.Sc] immunoreacted much more readily with the monoclonal antibody 1E4 than with 3F4, as previously reported for VPSPr Pr[P.sup.Sc] (14). Probed with 1E4, Tg mouse resPr[P.sup.Sc] exhibited a 5-band electrophoretic profile, similar to that of VPSPr (Figure 3). Deglycosylation by PNGase resulted in 3 resPr[P.sup.Sc] bands that co-migrated with the analogous VPSPr bands at [approximately equal to] 20 kDa, [approximately equal to] 17 kDa, and [approximately equal to] 7 kDa (Figure 3) (15). No definitely positive WB conducted with standard methods was observed in VPSPr-inoculated Tg(HuPrP129V)x3 and Tg(HuPrP129M)x2 mice (Table 1).
All negative controls, including noninoculated Tg mice and Tg mice inoculated with noninfectious BH, had negative WB. In contrast, WB were positive, with the classical 3-band profile, in all mice from the 3 Tg(HuPrP) lines challenged with BH from different sCJD subtypes used as positive controls (Table 3). WB examination of brains from 3 Tg(HuPrP129V)x8 mice challenged with VPSPr-129VV BH showed no evidence of Pr[P.sup.Sc] 35 dpi, indicating that the inoculum was too diluted to be detected or no longer present.
The second passage yielded a surprising finding. None of the 13 mice belonging to the Tg(HuPrP129V)x8 and Tg(HuPrP129M)x2 lines showed prion-related histologic lesions or had a definitely positive WB upon secondary transmission, even up to nearly 800 dpi (Table 4).
The experiments reported here, which probed transmissibility of VPSPr to Tg mice expressing human Pr[P.sup.C], yielded puzzling results. On first passage, all hosts remained asymptomatic, but 54% showed focal deposition of Pr[P.sup.Sc] in the form of prion plaques by immunohistochemical analysis. In 34% of animals, small amounts of resPr[P.sup.Sc] were demonstrated by WB (Figures 1, 3). The Pr[P.sup.Sc] recovered from affected mice recapitulated the electrophoretic profile and immunoreactivity features of the VPSPr-129VV Pr[P.sup.Sc], even after removal of the sugar moiety. However, mouse Pr[P.sup.Sc] was apparently more PK-resistant than the Pr[P.sup.Sc] from VPSPr-129VV case-patients (Figure 3) (15). In contrast, on second passage, all Tg mice were negative at clinical and histopathologic examinations and harbored no Pr[P.sup.Sc] that could be definitely identified by WB, even up to 800 dpi.
These findings pose several challenging questions. The first question concerns whether the Pr[P.sup.Sc] recovered on first passage represents the residual inoculum rather than de novo Pr[P.sup.Sc] generated by conversion of the host's Pr[P.sup.C]. We believe this possibility is made unlikely by our experiment showing that the Pr[P.sup.Sc] in the VPSPr inoculum was no longer detectable by immunohistochemical and WB analyses in Tg(HuPrP-129VV) mice 35 dpi. Furthermore, histopathologic changes and Pr[P.sup.Sc] detection, indicating VPSPr transmission, were observed only when the host and the inoculum were syngenic at PrP codon 129. This genotypic selectivity is not compatible with the notion that the Pr[P.sup.Sc] detected in the hosts was from the residual inoculum. Finally, several other studies have shown that Pr[P.sup.Sc] associated with the inoculum is rapidly cleared (12,26-30). These observations support the conclusion that histopathologic changes and the Pr[P.sup.Sc] recovered in the positive VPSPr-challenged mice result from de novo mouse Pr[P.sup.Sc] generated by templated conversion, although at a very low level. The lack of clinical signs in the affected mice can be easily explained by the characteristics and localization of the plaques and of the spongiform degeneration, both of which affected limited regions depopulated of neuronal cells and processes.
Prion plaques similar in type and topography to those we observed have been reported alone or associated with spongiform degeneration in mice challenged with prions of various origins (9,11,29-32). In 3 studies, plaque deposits seem to be especially similar to those observed by us. In the first, the plaques were detected on the second passage of vCJD in Tg mice expressing human Pr[P.sup.C]-129V (Tg152) (11,29). The second and third studies used Tg mice expressing mouse PrP harboring the P101L variation (101LL mice), which is the equivalent of the P102L human mutation linked to a GSS subtype (9,30). In the last 2 experiments, Tg101LL mice were challenged with "atypical" P102L GSS (i.e., GSS associated only with 7-kDa Pr[P.sup.Sc] PK-resistant fragment rather than with the "typical" P102L GSS that is also associated with the classical 3-band resPr[P.sup.Sc]) or with BH from TgGSS-22, a Tg mouse model of GSS in which prion disease spontaneously develops (9,30). All affected mice of these 3 studies remained asymptomatic like those of our study, further supporting the notion that focal prion plaque deposition in periventricular regions is not sufficient to produce major clinical signs. Despite the common histopathologic features, these mice were associated with electrophoretically distinct Pr[P.sup.Sc] species. In the experiment of vCJD transmission, Pr[P.sup.Sc] harvested from challenged Tg152 mice showed the classical 3 PK-resistant bands as in vCJD, but they displayed a higher molecular mass than in vCJD (11). Minimal quantity of resPr[P.sup.Sc] recovered at [approximately equal to] 30 kDa was detected only in 1 of 5 plaque-harboring 101LL mice challenged with atypical P102L GSS (9), whereas 101LL mice inoculated with TgGSS-22 BH showed no detectable Pr[P.sup.Sc] by WB (30). Although to some extent the variability of the Pr[P.sup.Sc] electrophoretic profiles between the experiments with Tg101LL and our experiments might be due to variations in WB methods, the Pr[P.sup.Sc] diversity in these 3 studies and in our study suggests that focal plaque formation at the border between the hippocampus and corpus callosum is not strictly Pr[P.sup.Sc] strain specific. However, this brief review indicates that peri-hippocampal plaque deposition is preferentially detected in hosts challenged with Pr[P.sup.Sc] species that form plaques in the natural disease, such as vCJD, GSS, and VPSPr.
The lack of histologic lesions and Pr[P.sup.Sc] on second passage in both Tg(HuPrP129V) and Tg(HuPrP129M) mice challenged with BH from the most severely affected first-passage mice is unusual. However, comparable findings have been reported in at least 2 previous studies. In the first, 101LL mice challenged with affected TgGSS-22 BH (a Tg mouse in which a GSS-like disease spontaneously develops) harbored fewer plaques on second passage than on first, suggesting decreased replication of the seed on second passage (9,30). In the second study, first passage of BH from cattle affected by bovine spongiform encephalopathy to Tg152 mice (expressing human Pr[P.sup.C]129V) resulted in clinical disease associated with diffuse brain deposition of PrP as demonstrated by immunostaining (11), even though no resPr[P.sup.Sc] could be demonstrated by WB. On second passage in the same Tg152 mice, no evidence of prion disease could be demonstrated either by PrP immunostaining or WB, as in our study (11). However, BH from these negative Tg152 produced a full prion disease after inoculation into wild-type FVB mice. This remarkable finding indicates that prion transmissibility (or infectivity) can be sustained in hosts with no demonstrable prion diseases (according to commonly used methods), and that it can be rescued through passage to an appropriate host (11).
Interpreting our findings also in the light of the above data, we propose that normal human Pr[P.sup.C] is not a suitable substrate (or mouse brain is not a favorable environment) to sustain conversion to VPSPr Pr[P.sup.Sc]. Thus, long incubations are required to induce modest and asymptomatic Pr[P.sup.Sc] deposition. Nevertheless, the Pr[P.sup.Sc] generated in the host on first passage seems to match the conformation of the Pr[P.sup.Sc] from the inoculum, based on the finding that PK-resistant Pr[P.sup.Sc] fragments of similar size are recovered from host and donor preparations. This also indicates that little or no Pr[P.sup.Sc] adaptation has occurred during the first passage (32). The apparent failure of the second passage to transmit detectable disease might be due to the inadequate amplification of VPSPr Pr[P.sup.Sc] during primary transmission, which would result in a second passage Pr[P.sup.Sc] inoculum more diluted than the VPSPr brain extract used in the primary transmission. This line of reasoning raises the possibility that if VPSPr Pr[P.sup.Sc] were exposed to a favorable PrP substrate (or brain environment), it might replicate efficiently. This conjecture is reinforced by 2 recent findings. First, preliminary findings show that VPSPr can be transmitted to bank voles more easily than to the Tg(HuPrP) used in the present experiments (33). Second, transmissibility of GSS linked to the A117V mutation has been recently demonstrated (10). GSS-A117V is commonly viewed as a "classic" GSS subtype, given the distinct features of its phenotype that is characterized by prominent prion plaques with limited spongiform degeneration and a Pr[P.sup.Sc] WB profile dominated by a highly PK-resistant fragment of 7-8 kDa (34). Early failures to transmit GSS-A117V and the evidence that the presence of the A117V mutation altered the topology of PrP led to the conclusions that 1) GSS-A117V was not transmissible and 2) its underlying pathogenetic mechanism was not based on a Pr[P.sup.C]-to-Pr[P.sup.Sc] conversion process (8).
After inoculation with BH from GSS-A117V-affected patients, Tg mice expressing human PrP, harboring the A117V mutation, developed a prion disease associated with a histologic phenotype and Pr[P.sup.Sc] that roughly recapitulated those of the human disease. However, only one fourth of the inoculated mice were symptomatic with incubation periods >600 days, whereas more than half harbored plaques, Pr[P.sup.Sc], or both (10). No second passage was reported. This study shows that an allegedly nontransmissible prion disease can be transmitted (at least at first passage) if a suitable host is selected.
In conclusion, we propose that VPSPr is transmissible and, therefore, is an authentic prion disease. However, transmissibility cannot be sustained through serial passages presumably because human Pr[P.sup.C] (or the mouse brain environment) cannot efficiently convert and propagate the VPSPr Pr[P.sup.Sc] species. If this is the case, uncovering the properties of human PrP that are required to replicate more efficiently the prion strains associated with VPSPr may help clarify the Pr[P.sup.Sc] mode of formation in this intriguing disease.
We thank Miriam Warren and Katie Glisic for their skillful contributions to the histologic study and manuscript editing, respectively.
This study was supported by National Institutes of Health awards AG14359 and NS062787, Centers for Disease Control and Prevention award UR8/CCU515004, Charles S. Britton Fund, and Spanish Ministerio de Ciencia e Innovacion AGL201237988-C04-04.
Dr Notari is an instructor at Case Western Reserve University, Cleveland, Ohio, USA. His research interests include prion diseases with particular focus on the characteristics of Pr[P.sup.Sc] in different prion strains and their relationships with infectivity.
(1.) Prusiner SB. Biology and genetics of prions causing neurodegeneration. Annu Rev Genet. 2013;47:601-3. http://dx.doi.org/10.1146/annurev-genet-110711- 155524
(2.) Surewicz WK, Apostol MI. Prion protein and its conformational conversion: a structural perspective. Top Curr Chem. 2011;305:13567. http://dx.doi.org/10.1007/128_2011_165
(3.) Aguzzi A, Falsig J. Prion propagation, toxicity and degradation. Nat Neurosci. 2012;15:936-9. http://dx.doi.org/10.1038/nn.3120
(4.) Sandberg MK, Al-Doujaily H, Sharps B, Clarke AR, Collinge J. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature. 2011;470:540-2. http://dx.doi.org/10.1038/nature09768
(5.) Gambetti P, Cali I, Notari S, Kong Q, Zou WQ, Surewicz WK. Molecular biology and pathology of prion strains in sporadic human prion diseases. Acta Neuropathol. 2011;121:79-90. http://dx.doi.org/10.1007/s00401-010-0761-3
(6.) Weissmann C, Flechsig E. PrP knock-out and PrP transgenic mice in prion research. Br Med Bull. 2003;66:43-60. http://dx.doi.org/10.1093/bmb/66.1.43
(7.) Kong Q, Surewicz WK, Petersen RB, Zou WQ, Chen SG, Gambetti P, et al. Inherited Prion Disease. In: Prusiner SB, editor. Prion biology and diseases. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory [P.sup.res]s; 2004. p. 673-775.
(8.) Hegde RS, Mastrianni JA, Scott MR, DeFea KA, Tremblay P, Torchia M, et al. A transmembrane form of the prion protein in neurodegenerative disease. Science. 1998;279:827-34. http://dx.doi.org/10.1126/science.279.5352.827
(9.) Piccardo P, Manson JC, King D, Ghetti B, Barron RM. Accumulation of prion protein in the brain that is not associated with transmissible disease. Proc Natl Acad Sci US A. 2007;104:4712-7. http://dx.doi.org/10.1073/pnas.0609241104
(10.) Asante EA, Linehan JM, Smidak M, Tomlinson A, Grimshaw A, Jeelani A, et al. Inherited prion disease A117V is not simply a proteinopathy but produces prions transmissible to transgenic mice expressing homologous prion protein. PLoS Pathog. 2013;9:e1003643. http://dx.doi.org/10.1371/journal.ppat.1003643
(11.) Wadsworth JD, Asante EA, Desbruslais M, Linehan JM, Joiner S, Gowland I, et al. Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science. 2004;306:1793-6. http://dx.doi.org/10.1126/science.1103932
(12.) Race R, Meade-White K, Raines A, Raymond GJ, Caughey B, Chesebro B. Subclinical scrapie infection in a resistant species: persistence, replication, and adaptation of infectivity during four passages. J Infect Dis. 2002; 186 (Suppl 2):S166-70. http://dx.doi.org/10.1086/344267
(13.) Hegde RS, Tremblay P, Groth D, DeArmond SJ, Prusiner SB, Lingappa VR. Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature. 1999;402:822-6. http://dx.doi.org/10.1038/45574
(14.) Gambetti P, Dong Z, Yuan J, Xiao X, Zheng M, Alshekhlee A, et al. A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol. 2008;63:697-708. http://dx.doi.org/10.1002/ana.21420
(15.) Zou WQ, Puoti G, Xiao X, Yuan J, Qing L, Cali I, et al. Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Ann Neurol. 2010;68:162-72. http://dx.doi.org/10.1002/ana.22094
(16.) Head MW, Yull HM, Ritchie DL, Langeveld JP, Fletcher NA, Knight RS, et al. Variably protease-sensitive prionopathy in the UK: a retrospective review 1991-2008. Brain. 2013;136:1102-15. http://dx.doi.org/10.1093/brain/aws366
(17.) Puoti G, Bizzi A, Forloni G, Safar JG, Tagliavini F, Gambetti P. Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol. 2012;11:618-28. http://dx.doi.org/10.1016/S14744422(12)70063-7
(18.) Xiao X, Yuan J, Haik S, Cali I, Zhan Y, Moudjou M, et al. Glycoform-selective prion formation in sporadic and familial forms of prion disease. PLoS ONE. 2013;8:e58786. http://dx.doi.org/10.1371/journal.pone.0058786
(19.) Gambetti P, Kong Q, Zou W, Parchi P, Chen SG. Sporadic and familial CJD: classification and characterization. Br Med Bull. 2003;66:213-39. http://dx.doi.org/10.1093/bmb/66.E213
(20.) Padilla D, Beringue V, Espinosa JC, Andreoletti O, Jaumain E, Reine F, et al. Sheep and goat BSE propagate more efficiently than cattle BSE in human PrP transgenic mice. PLoS Pathog. 2011;7:e1001319. http://dx.doi.org/10.1371/journal.ppat.1001319
(21.) Fischer M, Rulicke T, Raeber A, Sailer A, Moser M, Oesch B, et al. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J. 1996;15:1255-64.
(22.) Kong Q, Huang S, Zou W, Vanegas D, Wang M, Wu D, et al. Chronic wasting disease of elk: transmissibility to humans examined by transgenic mouse models. J Neurosci. 2005;25:7944-9. http://dx.doi.org/10.1523/JNEUROSCI.2467-05.2005
(23.) Sailer A, Bueler H, Fischer M, Aguzzi A, Weissmann C. No propagation of prions in mice devoid of PrP. Cell. 1994;77:967-8. http://dx.doi.org/10.1016/0092-8674(94)90436-7
(24.) Paxinos K, Franklin G, editors. The mouse brain in stereotaxic coordinated. 2nd ed. San Diego (CA): Academic [P.sup.res]s; 2001.
(25.) Yuan J, Dong Z, Guo JP, McGeehan J, Xiao X, Wang J, et al. Accessibility of a critical prion protein region involved in strain recognition and its implications for the early detection of prions. Cell Mol Life Sci. 2008;65:631-43. http://dx.doi.org/10.1007/s00018-0077478-z
(26.) Bueler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, et al. Mice devoid of PrP are resistant to scrapie. Cell. 1993;73:133947. http://dx.doi.org/10.1016/0092-8674(93)90360-3
(27.) Race R, Raines A, Raymond GJ, Caughey B, Chesebro B. Long-term subclinical carrier state precedes scrapie replication and adaptation in a resistant species: analogies to bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease in humans. J Virol. 2001;75:1010612. http://dx.doi.org/10.U28/JVI.75.21.10106-10112.2001
(28.) Safar JG, DeArmond SJ, Kociuba K, Deering C, Didorenko S, Bouzamondo-Bernstein E, et al. Prion clearance in bigenic mice. J Gen Virol. 2005;86:2913-23. http://dx.doi.org/10.1099/vir.0.80947-0
(29.) Wadsworth JD, Joiner S, Linehan JM, Desbruslais M, Fox K, Cooper S, et al. Kuru prions and sporadic Creutzfeldt-Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice. Proc Natl Acad Sci U S A. 2008;105:3885-90. http://dx.doi.org/10.1073/pnas.0800190105
(30.) Piccardo P, King D, Telling G, Manson JC, Barron RM. Dissociation of prion protein amyloid seeding from transmission of a spongiform encephalopathy. J Virol. 2013;87:12349-56. http://dx.doi.org/10.1128/JVI.00673-13
(31.) Makarava N, Kovacs GG, Savtchenko R, Alexeeva I, Budka H, Rohwer RG, et al. Genesis of mammalian prions: from noninfectious amyloid fibrils to a transmissible prion disease. PLoS Pathog. 2011;7:e1002419. http://dx.doi.org/10.1371/journal.ppat.1002419
(32.) Tamguney G, Giles K, Oehler A, Johnson NL, DeArmond SJ, Prusiner SB. Chimeric elk/mouse prion proteins in transgenic mice. J Gen Virol. 2013;94:443-52. http://dx.doi.org/10.1099/vir. 0.045989-0
(33.) Nonno R, Di Bari M, Pirisinu L, D'Agostino C, Marcon S, Riccardi G, et al. Variably protease-sensitive prionopathy is transmissible in bank voles. Prion. 2012;6(S):6-7.
(34.) Pirisinu L, Nonno R, Esposito E, Benestad SL, Gambetti P, Agrimi U, et al. Small ruminant nor98 prions share biochemical features with human Gerstmann-Straussler-Scheinker disease and variably protease-sensitive prionopathy. PLoS ONE. 2013;8:e66405. http://dx.doi.org/10.1371/journal.pone.0066405
Silvio Notari,  Xiangzhu Xiao,  Juan Carlos Espinosa, Yvonne Cohen, Liuting Qing, Patricia Aguilar-Calvo, Diane Kofskey, Ignazio Cali, Laura Cracco, Qingzhong Kong, Juan Maria Torres, Wenquan Zou, and Pierluigi Gambetti
Author affiliations: Case Western Reserve University, Cleveland, Ohio, USA (S. Notari, X. Xiao, Y. Cohen, L. Qing, D. Kofskey, I. Cali, L. Cracco, Q. Kong, W. Zou, P. Gambetti); and Instituto Nacional de Investigacion y Tecnologla Agraria y Alimentaria, Madrid, Spain (J.C. Espinosa, P Aguilar-Calvo, J.M. Torres)
 These authors contributed equally to this article.
Address for correspondence: Pierluigi Gambetti or Wenquan Zou, Institute of Pathology, Case Western Reserve University, 2085 Adelbert Rd, Cleveland, OH 44106-4907, USA; email: email@example.com or firstname.lastname@example.org
Table 1. First passage VPSPr inoculations to Tg(HuPrP) harboring the same PrP 129 genotype as the inoculum * No. with clinical Inoculum Tg(HuPrP) signs/total VPSPr-129VV 1st (129V)x8([section]) 0/11 ([double dagger]) VPSPr-129VV 2nd 0/17 VPSPr-129VV 3rd 0/11 VPSPr-129VV 4th (129V)x3 0/9 VPSPr-129VV 5th 0/6 VPSPr-129MM 1st (129M)x2 0/6 VPSPr-129MM 2nd 0/6 (presymptomatic) Histology, immunohistochemistry No. Dpi Inoculum positive/total positive/total ([dagger]) VPSPr-129VV 1st 3/9 741 [+ or -] 76/741 [+ or -] 55 ([double dagger]) VPSPr-129VV 2nd 10/12 711 [+ or -] 65/722 [+ or -] 59 VPSPr-129VV 3rd 3/8 669 [+ or -] 92/651 [+ or -] 89 VPSPr-129VV 4th 7/9 655 [+ or -] 67/642 [+ or -] 104 VPSPr-129VV 5th 3/6 541 [+ or -] 96/642 [+ or -] 76 VPSPr-129MM 1st 4/6 678 [+ or -] 90/590 [+ or -] 154 VPSPr-129MM 2nd 0/6 0/746 [+ or -] 59 (presymptomatic) PrPSc Western blot No. Dpi positive/total Inoculum positive/ total VPSPr-129VV 1st 4/11 768 [+ or -] 74/733 [+ or -] 71 ([double dagger]) VPSPr-129VV 2nd 6/17 635 [+ or -] 204/682 [+ or -] 131 VPSPr-129VV 3rd 3/10 642 [+ or -] 157/604 [+ or -] 140 VPSPr-129VV 4th NA NA VPSPr-129VV 5th NA NA VPSPr-129MM 1st NA NA VPSPr-129MM 2nd NA NA (presymptomatic) Dpi, days postinoculation; M, methionine; V, valine; NA, not available; VPSPr, variably protease-sensitive prionopathy associated with homozygous V or M at codon 129 of the PrP gene (VPSPr-129VV or VPSPr-129MM). ([dagger]) Dpi of positive mice compared with dpi of all mice (including positive mice). Each value represents the mean [+ or -] SD. ([double dagger]) Identifies the VPSPr case-patients providing the inoculum, i.e., inocula were obtained from 5 case-patients with VPSPr-129VV and 2 with VPSPr-129MM. ([section]) Refers to the presence of V or M at PrP residue 129 and expression level indicated as x normal. Table 2. First passage VPSPr inoculations to Tg(HuPrP) mice harboring different PrP 129 genotypes from those of the inocula * No. with Inoculum Tg(HuPrP) clinical signs/total VPSPr-129VV 6th ([double dagger]) (129M)x1([section]) 0/5 VPSPr-129VV 4th 0/4 VPSPr-129VV 5th 0/5 VPSPr-129MV 1st (129M)x2 0/9 VPSPr-129MV 2nd 0/6 VPSPr-129MV 3rd 0/4 VPSPr-129MV 4st (129V)x8 0/6 VPSPr-129MV 3rd 0/7 Histology, immunohistochemistry No. Dpi Inoculum positive/total positive/total ([dagger]) VPSPr-129VV 6th ([double dagger]) 0/5 0/643 [+ or -] 71 VPSPr-129VV 4th 0/4 0/659 [+ or -] 55 VPSPr-129VV 5th 0/5 0/757 [+ or -] 57 VPSPr-129MV 1st 0/9 0/745 [+ or -] 70 VPSPr-129MV 2nd 0/6 0/582 [+ or -] 101 VPSPr-129MV 3rd 0/4 0/694 [+ or -] 153 VPSPr-129MV 4st 0/6 0/586 [+ or -] 68 VPSPr-129MV 3rd 0/7 0/681 [+ or -] 102 PrPSc Western blot No. Dpi Inoculum positive/total positive/total VPSPr-129VV 6th ([double dagger]) NA NA VPSPr-129VV 4th NA NA VPSPr-129VV 5th NA NA VPSPr-129MV 1st NA NA VPSPr-129MV 2nd NA NA VPSPr-129MV 3rd NA NA VPSPr-129MV 4st NA NA VPSPr-129MV 3rd NA NA Dpi, days postinoculation; M, methionine; V, valine; NA, not available; VPSPr, variably protease-sensitive prionopathy associated with homozygosity V or M at codon 129 of the PrP gene (VPSPr-129VV or VPSPr-129MM). ([dagger]) Dpi of positive mice compared with dpi of all mice (including positive mice). Each value represents the mean [+ or -] SD. ([double dagger]) Identifies the VPSPr case-patients providing the inoculum, i.e., inocula were obtained from 5 case-patients with VPSPr-129VV and 2 with VPSPr-129MM. ([section]) Refers to the presence of V or M at PrP residue 129 and expression level indicated as x normal. Table 3. Control studies of VPSPr inoculations to Tg(HuPrP) * No. with Inoculum Tg(HuPrP) clinical signs/total Negative controls None (129V)x8 0/15 ([double dagger]) Noninfectious 0/17 Positive controls sCJDVV2 ([section]) (129V)x8 6/6 sCJDVVI 7/7 sCJDMMI (129M)x2 3/3 sCJDMM2 3/3 sCJDMV2 (129V)x3 6/6 Histology, immunohistochemistry No. Dpi Inoculum positive positive/total /total ([dagger]) Negative controls None 0/9 0/721 [+ or -] 43 Noninfectious 0/8 0/744 [+ or -] 15 Positive controls sCJDVV2 ([section]) 3/3 223 [+ or -] 13/223 [+ or -] 13 sCJDVVI 7/7 353 [+ or -] 12/353 [+ or -] 12 sCJDMMI 3/3 183 [+ or -] 22/183 [+ or -] 22 sCJDMM2 3/3 609 [+ or -] 139/609 [+ or -] 139 sCJDMV2 6/6 312 [+ or -] 4/312 [+ or -] 4 PrPSc Western blot No. Dpi Inoculum positive positive/total /total Negative controls None 0/4 0/704 [+ or -] 43 Noninfectious 0/5 0/749 [+ or -] 112 Positive controls sCJDVV2 ([section]) 6/6 223 [+ or -] 11/223 [+ or -] 11 sCJDVVI 7/7 353 [+ or -] 12/353 [+ or -] 12 sCJDMMI 3/3 183 [+ or -] 22/183 [+ or -] 22 sCJDMM2 3/3 609 [+ or -] 139/609 [+ or -] 139 sCJDMV2 NA NA Dpi, days postinoculation; M, methionine; V, valine; NA, not available; VPSPr, variably protease-sensitive prionopathy; sCJD sporadic Creutzfeldt-Jakob disease. ([dagger]) Dpi of positive mice compared with dpi of all mice (including positive mice). Each value represents the mean [+ or -] SD. ([double dagger]) Refers to the presence of V or M at PrP residue 129 and expression level indicated as x normal. ([section]) Identifies the sCJD case-patients providing the inoculum. Table 4. VPSPr inoculations to Tg(HuPrP): second passage * No. with clinical Inoculum Tg(HuPrP) signs/total Tg(HuPrP129V) inoculated with (129V)x8 0/10 VPSPr-129VV 2nd ([double ([section]) dagger]) Tg(HuPrP129M) inoculated with (129M)x2 0/3 VPSPr-129MM 1st Histology, immunohistochemistry No. Dpi Inoculum positive/ positive/total total ([dagger]) Tg(HuPrP129V) inoculated with 0/10 0/616 [+ or -] 135 VPSPr-129VV 2nd ([double dagger]) Tg(HuPrP129M) inoculated with 0/3 0/694 [+ or -] 51 VPSPr-129MM 1st PrPSc Western blot No. Dpi Inoculum positive/ positive/total total Tg(HuPrP129V) inoculated with 0/10 0/616 [+ or -] 135 VPSPr-129VV 2nd ([double dagger]) Tg(HuPrP129M) inoculated with NA NA VPSPr-129MM 1st Dpi, days postinoculation; M, methionine; V, valine; NA, not available; VPSPr, variably protease-sensitive prionopathy associated with homozygosity V or M at codon 129 of the PrP gene (VPSPr-129VV or VPSPr-129MM); ([dagger]) Dpi of positive mice compared with dpi of total mice (including the positive mice). Each value represents the mean [+ or -] SD. ([double dagger]) Identifies the Transgenic mice, inoculated with VPSPr in the first passage, providing the inoculum. ([section]) Refers to the presence of V or M at PrP residue 129 and expression level indicated as x normal.
|Printer friendly Cite/link Email Feedback|
|Author:||Notari, Silvio; Xiao, Xiangzhu; Espinosa, Juan Carlos; Cohen, Yvonne; Qing, Liuting; Aguilar-Calvo,|
|Publication:||Emerging Infectious Diseases|
|Date:||Dec 1, 2014|
|Previous Article:||Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels.|
|Next Article:||Seroconversion for infectious pathogens among UK Military personnel deployed to Afghanistan, 2008-2011.|